Interpreting immunogenicity in oncology clinical trials

By afschroeder • September 1, 2025

Galle PR, Reck M, Pinato DJ, Garcia-Campelo R, Finn RS, Cousin S, Zanghi J, Bernaards CA, Swanson SJ, Morris S, Song Y, Peters S. Interpreting immunogenicity in oncology clinical trials. Cancer Treat Rev. 2025 Aug 25;140:103016. doi: 10.1016/j.ctrv.2025.103016. Epub ahead of print. PMID: 40886486.

Tags: Hematology/Oncology, Publications

Related Posts

Five-Year Follow-Up of ZUMA-3: A Phase 1/2 Study of Brexucabtagene Autoleucel for the Treatment of Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

Oluwole OO, Ghobadi A, Cassaday RD, Park JH, Houot R, Logan AC, Boissel N, Leguay T, Bishop MR, Topp MS, O'Dwyer KM, Baer MR, Schiller[...]

Phase 2 Trial of 89Zr-Deferoxamine-Daratumumab for CD38-targeted Immuno-PET/CT Detection of Multiple Myeloma

Ulaner GA, Kuker RA, Diamond B, Hoffman J, Motwani P, Goldenson B, Homsi Y, Schiller G, Thomsen B, Vossen A, Kazandjian D, Landgren CO. Phase[...]

A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trial

Oh MS, Lisberg AE, Dumitras C, Tran LM, Salehi-Rad R, Krysan K, Lim RJ, Shabihkhani M, Romero T, Li S, Zeng W, Jing Z, Li[...]